Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Pınar Gürsoy ÖnerAli Murat TatliDilek ErdemErdem GokerEmir CelikNebi Serkan DemirciAbdullah SakinMuhammet Mustafa AtcıErtuğrul BayramTuğba Akın TelliBurak BilginAhmet BiliciBaran AkangunduzSevinç BalliAhmet DemirkazikFatih SelçukbiricikSerkan MenekseEyyüp CavdarAkın OzturkEsma Türkmen BekmezSerdal TurhalSadettin KilickapHasan Çağrı YildirimBaşak OyanAsude AksoyFatma Paksoy TurkozEngin KutNuran KatgiTeoman SakalarMurat AkyolHalil İbrahim EllezAtakan TopcuAtike Pınar ErdoğanKezban Nur PilanciEngin HedemHacı ArakNadiye AkdenizÖzkan AlanBurcu YaparDeniz NartPerran Fulden YumukPublished in: Journal of cancer research and clinical oncology (2022)
In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.